The Effect of Vitamin B12, Magnesium and Vitamin D in COVID-19 among Geriatric Patients
Authors/Creators
- 1. Assistant Professor, Department of Medicine, Pacific Institute of Medical Sciences, Umarda, Udaipur
Description
Introduction: The pandemic hit caused a high prevalence of COVID-19 and fatalities gloablly. This disease has affected various organ systems and causing systemic inflammation, other than respiratory symptoms. The pathophysiological mechanism also shown that lower levels of vitamin B12 caused disruption in gut microbiota and increased oxidative stress. Reduced levels of vitamins and magnesium, resulted from the infection of this disease, has led to further deterioration of the health status. Aims and Objectives: This study is intended to evaluate the effect of combination therapy of vitamin D, magnesium, and vitamin B12 in COVID-19 patients by analyzing the outcomes of the disease when this combination therapy is applied. Materials and Methods: This current study is a cohort observational prospective, in which 30 patients were given a combination of cholecalciferol (vitamin D3) of 1000 IU, magnesium oxide at 150 mg dose and methylcobalamine (Vitamin B12) of 500 µg, referred to as Intervention group. Another 25 patients were taken for comparison and referred to as Control group. The baseline data was collected, and the outcomes were observed and compared between the two groups. Results: The study also found that the duration required to run the management of COVID-19 is significantly less in Intervention group than control group (p<0.05). The study further added that the group which received the combination therapy required less oxygen therapy with or without ICU support (p<0.05). Conclusion: The study concluded that this combination therapy can improve the health status of COVID-19 patients by decreasing the probability to require oxygen therapy and ICU support. The study also concluded that this combined therapy can reduce the duration of hospitalization of COVID-19 patients.
Abstract (English)
Introduction: The pandemic hit caused a high prevalence of COVID-19 and fatalities gloablly. This disease has affected various organ systems and causing systemic inflammation, other than respiratory symptoms. The pathophysiological mechanism also shown that lower levels of vitamin B12 caused disruption in gut microbiota and increased oxidative stress. Reduced levels of vitamins and magnesium, resulted from the infection of this disease, has led to further deterioration of the health status. Aims and Objectives: This study is intended to evaluate the effect of combination therapy of vitamin D, magnesium, and vitamin B12 in COVID-19 patients by analyzing the outcomes of the disease when this combination therapy is applied. Materials and Methods: This current study is a cohort observational prospective, in which 30 patients were given a combination of cholecalciferol (vitamin D3) of 1000 IU, magnesium oxide at 150 mg dose and methylcobalamine (Vitamin B12) of 500 µg, referred to as Intervention group. Another 25 patients were taken for comparison and referred to as Control group. The baseline data was collected, and the outcomes were observed and compared between the two groups. Results: The study also found that the duration required to run the management of COVID-19 is significantly less in Intervention group than control group (p<0.05). The study further added that the group which received the combination therapy required less oxygen therapy with or without ICU support (p<0.05). Conclusion: The study concluded that this combination therapy can improve the health status of COVID-19 patients by decreasing the probability to require oxygen therapy and ICU support. The study also concluded that this combined therapy can reduce the duration of hospitalization of COVID-19 patients.
Files
IJPCR,Vol14,Issue5,Article113.pdf
Files
(314.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:5a32e1cf299cff1b60cf885fb31c7a5e
|
314.6 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-04-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue5,Article113.pdf
- Development Status
- Active
References
- 1. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterology 2020; 115:766–73. 2. Verity R, Okell LC, Dorigatti I, Wiskill P, Whittaker C, Imai C, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020; 20:669–77. 3. K. Mikkelsen, L. Stojanovska, M. Prakash, V. Apostolopoulos, The effects of vitamin B on the immune/cytokine network and their involvement in depression, Maturitas. 2017; 96:58–71. 4. Shakoor H, Feehan J, Mikkelsen K, Al Dhaheri AS, Ali HI, Platat C, Ismail LC, Stojanovska L, Apostolopoulos V. Be well: A potential role for vitamin B in COVID-19. Maturitas. 2021 Feb 1;144:108-11. 5. Baykal H, Ülger AF. Correlation of vitamin D level with the clinicalradiological severity of COVID-19 in geriatric patients. J Health Sci Med 2022; 5(3): 771-777. 6. Trapani V, Rosanoff A, Baniasadi S, Barbagallo M, Castiglioni S, GuerreroRomero F, Iotti S, Mazur A, Micke O, Pourdowlat G, Scarpati G, Wolf FI, Maier JA. The relevance of magnesium homeostasis in COVID-19. Eur J Nutr. 2022 Mar;61(2):625-636. 7. DiNicolantonio JJ, O'Keefe JH. Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in Covid-19 Patients. Mo Med. 2021; 118:68–73. 8. van Kempen TA, Deixler E. SARSCoV-2: influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP) metabolism and on severity of COVID-19. American Journal of Physiology-Endocrinology and Metabolism. 2021 Jan 1;320(1) :E2-6. 9. Grant WB. Vitamin D's role in reducing risk of SARS-CoV-2 and COVID-19 incidence, severity, and death. Nutrients. 2021 Dec 31;14 (1): 183. 10. Eskander M, Razzaque MS. Can maintaining optimal magnesium balance reduce the disease severity of COVID-19 patients? Frontiers in Endocrinology. 2022 Mar 29:501. 11. Tan CW, Ho LP, Kalimuddin S, Cherng BP, Teh YE, Thien SY, Wong HM, Tern PJ, Chandran M, Chay JW, Nagarajan C. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. 2020 Nov 1; 79:111017. 12. Negi S, Das DK, Pahari S, Nadeem S, Agrewala JN. Potential role of gut microbiota in induction and regulation of innate immune memory. Front Immunol 2019;10:2441. 13. Dhar D, Mohanty A. Gut microbiota and Covid-19—possible link and implications. Virus Res 2020;285 :198 018. 14. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut microbiota of patients with COVID19 during time of hospitalization [Epubahead of print]. Gastroenterology 2020. 15. Aguilar R. Fatigue symptom and oximetry sign in a patient with a positive Covid-19 antigen test for SarsCov-2. Journal of Medical Research and Health Sciences, 2022;5(8), 2165– 2176. 16. Dofitas B. Philippine COVID-19 Living clinical practice guidelines. Should protective physical barriers be used to prevent COVID-19? Philippine Soc Microbiol Infect Dis-PSMID. 2021; 6.